HormonesReview ArticlePaywall

Who Benefits From Testosterone Therapy in Older Men With Hypogonadism

A review of late-onset hypogonadism says testosterone therapy should be individualized by severity, benefit-risk balance, and the patient's acceptance of monitoring.

Wednesday, November 18, 2026 0 views
Published in Clin Geriatr Med
a physician reviewing blood test results with an older man in a bright clinic exam room

Summary

Testosterone levels in men drift downward with age. This review from endocrinologists at Harbor-UCLA looks at late-onset hypogonadism, a syndrome of impaired androgen production and/or sperm production in older men. The authors state that some older men with low testosterone may benefit from treatment while others may not. They argue the decision to prescribe should rest on how severe the hypogonadism is, the likely benefits and risks of therapy, and whether the patient is willing to accept those risks and the monitoring that comes with treatment. Choice of testosterone formulation should follow patient preference, pharmacokinetics, treatment burden, and cost. Only the abstract was available, so specific trial data, effect sizes, and safety numbers are not covered here. The takeaway is a framework for individualized decisions rather than a blanket recommendation for or against treating older men.

0:00--:--

Detailed Summary

Testosterone falls gradually as men age, and many older men and their physicians wonder when low levels are a treatable disease and when they are simply part of aging. This review addresses that question for hormone-focused clinicians and longevity-minded readers.

The authors, endocrinologists at Harbor-UCLA Medical Center and The Lundquist Institute, define hypogonadism in older men as a late-onset clinical syndrome of impaired androgen production and/or spermatogenesis. They note that aging is associated with a gradual decline in serum testosterone concentrations.

The abstract's central conclusion is that outcomes differ between patients: some older hypogonadal men may benefit from testosterone therapy, while others may not. The abstract does not report which outcomes improve, by how much, or which harms occur, so those details cannot be summarized here.

The practical message is a decision framework. Prescribing should be based on the severity of hypogonadism, an assessment of potential benefits and risks, and the patient's willingness to accept the risks of treatment and the monitoring it requires. Formulation choice should reflect patient preference, pharmacokinetics, treatment burden, and cost.

For readers, this means a low testosterone number alone is not the whole story. The syndrome, its severity, and the individual risk-benefit balance matter, and treatment is a shared decision with a physician, including ongoing monitoring.

Caveats are significant. This summary rests on the abstract only, because the full text is not open access. It is a narrative review, so it synthesizes existing evidence rather than presenting new trial data, and the abstract gives no specifics on evidence quality, effect sizes, cardiovascular or prostate safety, or formulation comparisons. Readers should consult the full article before drawing conclusions.

Key Findings

  • Late-onset hypogonadism is defined as impaired androgen production and/or spermatogenesis, with a gradual age-related decline in serum testosterone.
  • Some older hypogonadal men may benefit from testosterone therapy while others may not; response is individual.
  • Prescribing should weigh hypogonadism severity, potential benefits and risks, and the patient's acceptance of risks and monitoring.
  • Formulation choice depends on patient preference, pharmacokinetics, treatment burden, and cost.

Methodology

This is a narrative review article in Clinical Geriatrics Medicine. Only the abstract was available, so the search methods, evidence grading, and studies included are unknown. The authors report no conflicts of interest.

Study Limitations

This summary is based on the abstract only, as the full paper is not open access, so outcome data, effect sizes, and specific harms are not reported. As a narrative review, it may reflect author selection of evidence. Mechanism, function, and lifespan outcomes cannot be separated from the abstract.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: